Xience Xience
Abbott
Get Latest Data

XIENCE Safety Differentiators

XIENCE Stent Design: Low Stent Thrombosis Rates

A universal aim in the industry is to minimize the incidence of stent thrombosis (ST). XIENCE can point to extremely low stent thrombosis rates, even among complex patient populations.

Xience low thrombosis in complex patients
Xience low thrombosis in complex patients

The XIENCE coating technology is a key factor in minimizing stent thrombosis.

Protecting Patients from Stent Thrombosis

XIENCE VS OTHER DRUG-ELUTING STENTS

At rates of 0.0% and 0.1%, XIENCE outperforms other drug-eluting stents (DES) for 30-day stent thrombosis  rates in these studies:

  • The Resolute All Comers trial was designed to be representative of everyday clinical practice.7
  • The Platinum Plus trial examined the XIENCE and Promus Element stents.8
Xience vs Resolute and Xience vs Promus Element
Xience vs Resolute and Xience vs Promus Element
 

Protecting Complex Patients

XIENCE VS BARE METAL STENTS

Compared to bare metal stents (BMS) in a meta-analysis of all-comer complex patients, XIENCE was shown to save lives. 

Xience vs bare metal stents
Xience vs bare metal stents
the Science
Fluoropolymer Promotes Safety

Get the latest data

Sign up to receive the latest about XIENCE study results as they become available.


SIGN UP
Sign up

AP2944592-WBO Rev. A

References

† Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.


‡ Increased maximum expansion compared to other XIENCE Everolimus Eluting Coronary Stent System.

  1. Kaul U. TUXEDO Trial 2-year data. TCT 2016.  
  2. Teeuwen K, et al. PRISON IV Trial. JACC Cardiovasc Interv. 2016. doi: 10.1016/ j.jcin.2016.10.017.
  3. Stone GW, et al. EXCEL Trial. N Engl J Med. 2016;375:2223-2235. doi: 10.1056/NEJMoa1610227.
  4. Lam M. TWENTE Trial. Am Heart J.  2015;169:69-77. doi: 10.1016/j.ahj.2014.10.011.  
  5. Sabaté M. EXAMINATION Trial 5-year data. ESC 2015.
  6. de Belder A, et al. XIMA Trial. JACC. 2014;63:1371–1375. 
  7. Serruys PW, et al. Resolute All Comers Trial. N Engl J Med. 2010;363:136-146. doi: 10.1056/NEJMoa1004130.
  8. Fajadet J. Platinum Plus. TCT 2012.
  9. Valgimigli M. Meta-analysis. EuroPCR 2014. 
Share site

Caution: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use provided inside the product carton (when available), at eifu.abbottvascular.com or at Manuals.sjm.com for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Information contained herein for distribution outside the U.S. only. Check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force. 

Tests performed by and data on file at Abbott. Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.


Abbott International BVBA
Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium, Tel: 32.2.714.14.11

XIENCE V , XIENCE PRIME,  XIENCE Xpedition, and XIENCE Alpine are trademarks of the Abbott Group of Companies. Promus Element, Promus Element Plus, Promus Premier and Synergy are trademarks of Boston Scientific Corporation or its affiliates. Resolute, Resolute Integrity and Resolute Onyx are trademarks of Medtronic, Inc. Nobori and Ultimaster are trademarks of Terumo Corporation. BioMatrix and BioMatrix Flex are trademarks of Biosensors International. Orsiro is a trademark of Biotronik SE & Co. KG. Cypher is a trademark of Cordis, a Cardinal Health company.

©2017 Abbott. All rights reserved.

AP2944534-WBO Rev. C
Share site

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?
YES NO

Are you a healthcare professional in the
U.S. or outside of the U.S.?

U.S. Outside of U.S.